Which conditions contributing to the Charlson score predict survival after radical prostatectomy?

被引:18
作者
Froehner, M
Koch, R
Litz, R
Oehlschlaeger, S
Wirth, MP
机构
[1] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Urol, D-01307 Dresden, Germany
[2] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Med Stat & Biometry, D-01307 Dresden, Germany
[3] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Anesthesiol, D-01307 Dresden, Germany
关键词
prostate; prostatic neoplasms; prostatectomy; prognosis; comorbidity;
D O I
10.1097/01.ju.0000108138.36333.09
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The Charlson score is likely to be the most frequently used comorbidity measure in prostate cancer. However, to our knowledge the individual prognostic significance of contributing conditions has not been previously studied in a radical prostatectomy sample. Materials and Methods: A total of 444 consecutive patients were entered into this study. The 19 conditions contributing to the Charlson score were obtained from the preoperative cardiopulmonary risk assessment and the hospital discharge document. Mantel-Haenszel hazard ratios were estimated for comorbid (noncancer) and overall survival. Thereafter, the Charlson score was refined by excluding conditions with low predictive value. Results: Mean followup was 5.9 years. Only 3 single conditions (congestive heart failure; peripheral vascular disease and severe renal disease) were significantly associated with excess overall mortality. Concerning comorbid mortality, in addition to these 3 diseases, chronic pulmonary disease was associated with increased risk. Refinement of the Charlson score improved the circumscription of patients at risk for premature death after radical prostatectomy. Conclusions: This study suggests that restricting the Charlson score to some clinically meaningful diseases may increase its usefulness in candidates for radical prostatectomy. The conventional Charlson score did not add clinically meaningful information supplementary to congestive heart failure, which is the most important single contributing condition.
引用
收藏
页码:697 / 699
页数:3
相关论文
共 11 条
[1]   The impact of co-morbidity on life expectancy among men with localized prostate cancer [J].
Albertsen, PC ;
Fryback, DG ;
Storer, BE ;
Kolon, TF ;
Fine, J .
JOURNAL OF UROLOGY, 1996, 156 (01) :127-132
[2]  
Barry MJ, 2001, CANCER-AM CANCER SOC, V91, P2302, DOI 10.1002/1097-0142(20010615)91:12<2302::AID-CNCR1262>3.3.CO
[3]  
2-G
[4]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[5]   Sociodemographic and clinical risk characteristics of patients with prostate cancer within the veterans affairs health care system: Data from capsure [J].
Cooperberg, MR ;
Lubeck, DP ;
Penson, DF ;
Mehta, SS ;
Carroll, PR ;
Kane, CJ .
JOURNAL OF UROLOGY, 2003, 170 (03) :905-908
[6]   Hormone therapy for locally advanced prostate cancer [J].
Fowler, JE ;
Bigler, SA ;
White, PC ;
Duncan, WL .
JOURNAL OF UROLOGY, 2002, 168 (02) :546-549
[7]   Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy [J].
Fowler, JE ;
Terrell, FL ;
Renfroe, DL .
JOURNAL OF UROLOGY, 1996, 156 (05) :1714-1718
[8]   Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy [J].
Froehner, M ;
Koch, R ;
Litz, R ;
Heller, A ;
Oehlschlaeger, S ;
Wirth, MP .
UROLOGY, 2003, 62 (04) :698-701
[9]   A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer [J].
Holmberg, L ;
Bill-Axelson, A ;
Helgesen, F ;
Salo, JO ;
Folmerz, P ;
Häggman, M ;
Andersson, S ;
Spångberg, A ;
Busch, C ;
Nordling, S ;
Palmgren, J ;
Adami, HO ;
Johansson, J ;
Norlén, BJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (11) :781-789
[10]   The impact of co-morbid disease on cancer control and survival following radical cystectomy [J].
Miller, DC ;
Taub, DA ;
Dunn, RL ;
Montie, JE ;
Wei, JT .
JOURNAL OF UROLOGY, 2003, 169 (01) :105-109